A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy (Fuchs)
A Randomized, Open-Label, Parallel-Group Study to Evaluate the Safety and Efficacy of Two Dosing Regimens of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy
Sponsor: Aerie Pharmaceuticals
Listed as NCT04498169, this PHASE2 trial focuses on Corneal Edema and remains completed. Sponsored by Aerie Pharmaceuticals, it has been updated 9 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Sep 2021 — Sep 2022 [monthly]
Completed PHASE2
Status: Recruiting → Completed
▶ Show 4 earlier versions
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — Jun 2021 [monthly]
Recruiting PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2020 — Nov 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Aerie Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .